South & Central America Antibody Drug Conjugates Market Report 2031 by Segments, Geography, Dynamics, Recent Developments, and Strategic Insights

The South and Central America Antibody Drug Conjugates Market size is expected to reach US$ 1,062.2 Million by 2031 from US$ 254.8 Million in 2023. The market is estimated to record a CAGR of 19.5% from 2023 to 2031.

Executive Summary and South and Central America Antibody Drug Conjugates Market Analysis:

The South and Central America antibody-drug conjugates (ADC) market, which is further divided into Brazil, Argentina, and the Rest of the region, is growing significantly due to various factors. Rising awareness regarding cancer and its increasing incidence has fueled the need for sophisticated and targeted treatments such as ADCs. Governments and healthcare associations are fervently encouraging early detection and treatment procedures, which are also contributing to market growth. Also, an increasing number of clinical trials in Brazil and Argentina is driving research and development activities at a faster pace and triggering the launch of innovative ADC therapies. Supportive government policies and new oncology drug approvals from the government are also supporting the growth of the market. Brazil, with its strong healthcare infrastructure and investment in biotechnology, has the largest, followed by Argentina and other nations, which are becoming significant contributors through enhancing access to healthcare and partnerships with international pharmaceutical companies.

South & Central America Antibody Drug Conjugates Market: Strategic Insights

South and Central America Antibody Drug Conjugates Market Segmentation Analysis:

• By Technology, the South and Central America Antibody Drug Conjugates Market is segmented into Cleavable Linker and Non-cleavable Linker. Cleavable Linker held a larger share of the market in 2023.
• By Application, the South and Central America Antibody Drug Conjugates Market is segmented into Blood Cancer, Brain Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, and Others. Breast Cancer held the largest share of the market in 2023.
• By Target, the South and Central America Antibody Drug Conjugates Market is segmented into HER2, CD22, CD30, and Others. Others held the largest share of the market in 2023.
• By Distribution Channel, the South and Central America Antibody Drug Conjugates Market is segmented into Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies. Hospital Pharmacies held the largest share of the market in 2023.

South & Central America Antibody Drug Conjugates Market Players Density: Understanding Its Impact on Business Dynamics

The South & Central America Antibody Drug Conjugates Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

South and Central America Antibody Drug Conjugates Market Outlook

The expansion into new indications is creating significant opportunities in the antibody-drug conjugates market. As antibody-drug conjugates are primarily designed to deliver cytotoxic agents directly to cancer cells while sparing healthy tissues, their ability to target specific tumor-associated antigens makes them highly versatile. This versatility allows for exploring antibody-drug conjugate applications beyond their initial indications, i.e., hematological malignancies and certain solid tumors. Many cancers currently lack adequate treatment options, and introducing antibody-drug conjugates targeting new biomarkers can provide innovative therapies for these challenging conditions. For instance, antibody-drug conjugates are being investigated for treating cancers such as breast, lung, and bladder cancers, where traditional therapies may not yield satisfactory results. In Brazil, in November 2022, the indication for trastuzumab deruxtecan expanded. It was approved for patients with metastatic or unresectable HER2-low breast cancer who had received systemic therapy. Previously, it was only for those with HER2-positive metastatic or unresectable breast cancer who had undergone two or more anti-HER2 treatments. This change increased the number of eligible patients from around 383 to 23,000. It also raised the total treatment cost projection from about BRL 467,970,786 to BRL 26,048,234,160. Additionally, the collaboration between pharmaceutical companies and research institutions fosters innovation in antibody-drug conjugate development. These partnerships often focus on identifying novel targets and optimizing linker technologies to enhance the efficacy and safety profiles of conjugates. Moreover, with the discovery and validation of new targets, antibody-drug conjugates are being further investigated for their potential utilization in the treatment of a broader range of cancer types. By addressing unmet medical needs, benefiting from favorable regulatory conditions, capitalizing on the rising prevalence of cancer, and fostering collaborative innovation, antibody-drug conjugates are poised to play a pivotal role in the future of targeted cancer therapies. Thus, an expansion into new indications presents a wealth of opportunities for the antibody-drug conjugates market.

South and Central America Antibody Drug Conjugates Market Country Insights

By country, the South and Central America Antibody Drug Conjugates Market is segmented into Brazil, Argentina, and the Rest of South and Central America. Brazil held the largest share in 2023.

In Brazil, the rise in cancer cases, particularly in breast and lung cancers, has resulted in a greater demand for effective treatment options. The approval and introduction of antibody-drug conjugates such as Kadcyla and Adcetris have equipped oncologists with advanced tools to target cancer cells directly, ultimately improving patient outcomes. As these antibody-drug conjugates target specific cancer cells and release toxic drugs into the cancer cells, the utilization of such therapies for the treatment of cancer in the country is also expected to rise in the coming years. The Brazilian government has been implementing policies designed to improve access to cancer treatments, including innovative therapies such as antibody-drug conjugates. For instance, in September 2022, the Ministry of Health (MoH) announced that it plans to cover trastuzumab emtansine, known as Kadcyla (produced by Roche), under the Unified Health System (SUS) for use as a monotherapy in HER2-positive breast cancer. Under this initiative, MoH provides Kadcyla free of charge to cancer patients through the Brazilian Public Health System. In addition, initiatives that provide funding for cancer care and support research into new therapeutic options are positively contributing to the growth of the antibody-drug conjugates market.

South and Central America Antibody Drug Conjugates Market Company Profiles

Some of the key players operating in the market include GSK Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Bristol-Myers Squibb Co, Johnson & Johnson, Takeda Pharmaceutical Co Ltd, AstraZeneca Plc, Astellas Pharma Inc, AbbVie Inc, Merck KGaA, Gilead Sciences Inc, BioNTech SE, Daiichi Sankyo Co Ltd, RemeGen Co Ltd, and ADC Therapeutics SA.

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

South and Central America Antibody Drug Conjugates Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note:

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise